Table 1. Baseline Clinicopathologic and Laboratory Characteristics.
| Characteristic | No. (%) | P value | ||
|---|---|---|---|---|
| All (N = 74) | ECOG PS score | |||
| 0-1 (n = 45) | ≥2 (n = 29) | |||
| ECOG PS | ||||
| 0 | 6 (8.1) | 6 (13.3) | 0 | NA |
| 1 | 39 (52.7) | 39 (86.7) | 0 | |
| 2 | 25 (33.8) | 0 | 25 (86.2) | |
| 3 | 4 (5.4) | 0 | 4 (13.8) | |
| Age, median (range), y | 68.5 (33-87) | 65 (33-87) | 72 (42-87) | .003 |
| Women | 36 (48.7) | 22 (48.9) | 14 (48.3) | >.99 |
| Race | ||||
| White | 53 (71.6) | 32 (71.1) | 21 (72.4) | .64 |
| African American | 13 (17.6) | 7 (15.6) | 6 (20.7) | |
| Asian | 8 (10.8) | 6 (13.3) | 2 (6.9) | |
| Body mass index, median (range)a | 24.8 (13.1-47.7) | 24.3 (13.1-47.7) | 25.1 (17.3-40.9) | .27 |
| Obesity | 12 (16.2) | 4 (8.9) | 8 (27.6) | .05 |
| Ever smoked | 66 (89.2) | 41 (91.1) | 25 (86.2) | .70 |
| Comorbidities | ||||
| Simplified comorbidity score, median (range) | 9 (0-17) | 8 (0-17) | 9 (2-14) | .39 |
| Hypertension | 36 (48.6) | 19 (42.2) | 17 (58.6) | .23 |
| Diabetes | 10 (13.5) | 6 (13.3) | 4 (13.8) | >.99 |
| Cardiovascular | 42 (56.8) | 23 (51.1) | 19 (65.5) | .24 |
| Respiratory | 23 (31.1) | 11 (24.4) | 12 (41.14) | .19 |
| Creatinine clearance, mL/min/1.73 m2 | ||||
| <60 | 26 (35.1) | 15 (33.3) | 11 (37.9) | .80 |
| <30 | 3 (4.1) | 2 (4.4) | 1 (3.4) | >.99 |
| VTE | 12 (16.2) | 6 (13.3) | 6 (20.7) | .52 |
| Histology | ||||
| Nonsquamous | 52 (70.3) | 33 (73.3) | 19 (65.5) | .62 |
| Squamous | 19 (25.7) | 11 (24.4) | 8 (27.6) | |
| Poorly differentiated | 3 (4) | 1 (2.2) | 2 (6.9) | |
| Driver alterationsb | ||||
| None | 29 (42.6) | 19 (45.2) | 10 (38.5) | .90 |
| KRAS | 29 (42.6) | 17 (4.5) | 12 (46.2) | |
| EGFR | 4 (5.9) | 2 (4.8) | 2 (7.7) | |
| Others | 6 (8.8) | 4 (9.5) | 2 (7.7) | |
| ALK | 1 (1.5) | 1 (2.4) | 0 (0) | |
| RET | 1 (1.5) | 1 (2.4) | 0 (0) | |
| ERBB2 | 2 (2.9) | 2(4.8) | 0 (0) | |
| MET | 1 (1.5) | 0 (0) | 1 (3.8) | |
| BRAF | 1 (1.5) | 0 (0) | 1 (3.8) | |
| PD-L1 TPS, % | ||||
| Median (range) | 75 (1-100) | 80 (2-95) | 50 (1-100) | .09 |
| ≥50 | 53 (71.6) | 36 (80) | 17 (58.6) | .07 |
| Sites of metastases | ||||
| Median (range), No. | 2 (0-7) | 2 (0-7) | 2 (1-5) | .14 |
| Lung/pleura | 42 (56.8) | 25 (55.6) | 17 (58.6) | .82 |
| Lymph node | 33 (44.6) | 18 (40) | 15 (51.7) | .35 |
| Brain | 25 (33.8) | 16 (35.6) | 9 (31.0) | .80 |
| Bone | 34 (45.9) | 18 (40) | 16 (55.2) | .24 |
| Liver | 10 (13.5) | 6 (13.3) | 4 (13.8) | >.99 |
| Adrenal | 9 (12.2) | 5 (11.1) | 4 (13.8) | .73 |
| Others | 14 (18.9) | 6 (13.3) | 8 (27.6) | .14 |
| Line of therapy | ||||
| First | 54 (72.9) | 33 (73.3) | 21 (72.4) | >.99 |
| Second or greater | 20 (27.0) | 12 (26.7) | 8 (27.6) | |
| WBC, median (range), /μL | 7800 (3300-37 500) | 7600 (3300-23 400) | 7900 (4700-37 500) | .18 |
| ANC, median (range), /μL | 5700 (1900-22 400) | 5500 (1900-2300) | 6200 (3400-22 400) | .06 |
| Creatinine, median (range), mg/dL | 0.9 (0.4-4.2) | 0.9 (0.4-4.2) | 0.9 (0.4-2.3) | .87 |
Abbreviations: ANC, absolute neutrophil count; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score; VTE, venous thromboembolic disease; WBC, white blood cell count.
SI conversion factors: To convert ANC and WBC to ×109 per microliter, multiply by 0.001; creatinine to micromoles per liter, multiply by 88.4; creatinine clearance rate to milliliter per second per meters squared, multiply by 0.0167.
a
Body mass index was calculated as weight in kilograms divided by height in meters squared.
b
Driver alterations available for 68 patients (42 [61.8%] with ECOG PS of 1-2; 26 [38.2%] with ECOG PS of ≥2).